Neuro-Oncology News

Cytoreductive surgery may be an effective treatment option for specific subgroups of patients with primary central nervous system lymphoma, according to results of a systematic review.

Childhood cancer accounted for 11.5 million years of healthy life lost in 2017, with lower-resource nations facing a significantly larger burden than high-income countries, according to an analysis of the Global Burden of Disease Study published in The Lancet Oncology.

Although median and short-term OS rates have improved for glioblastoma, still only a small proportion of patients achieve 5-year survival, according to study results published in Mayo Clinic Proceedings.

The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

FDA-approved oncology agents took a median 6.5 years to proceed from first-in-human to first-in-child clinical trials, according to research published in European Journal of Cancer.

Researchers from Heidelberg University Hospital and the German Cancer Research Center have developed a novel technology that involves machine learning methods trained on standard MRI to assess treatment response among patients with glioblastoma, according to a press release.

Certain birth defects appeared significantly associated with increased risk for childhood cancer, according to results of a population-based cohort study of more than 10 million births published in JAMA Oncology.

by John Andrew Boockvar, MD, and Marc Symons, PhD

Cancer Immunotherapy Month is observed every June.

CHICAGO — Selinexor induced antitumor activity with durable responses and disease stabilization among patients with recurrent glioblastoma, according to phase 2 study results presented at ASCO Annual Meeting.